What is the primary treatment approach for rheumatoid arthritis?

The primary treatment approach for rheumatoid arthritis involves the use of disease-modifying antirheumatic drugs (DMARDs), with methotrexate being one of the most commonly used and effective agents. Methotrexate works by inhibiting the proliferation of lymphocytes and suppressing the immune response, thereby reducing inflammation and slowing disease progression.

In addition to methotrexate, tumor necrosis factor (TNF) inhibitors are also used as part of the treatment regimen. These biologic agents target specific components of the immune system involved in the inflammatory process of rheumatoid arthritis, leading to significant improvements in symptoms and function for many patients.

The combination of methotrexate and TNF inhibitors allows for a more comprehensive approach to managing the disease, particularly in patients who have not responded adequately to methotrexate alone. This approach can help achieve better control of disease activity, reduce joint damage, and improve patients' quality of life.

Other treatment options, such as NSAIDs and corticosteroids, may provide symptomatic relief for inflammation and pain but do not address the underlying disease process in the same way that DMARDs do. Antibiotics are not relevant to the treatment of rheumatoid arthritis, as this condition is not caused by an infection.